Massachusetts General Hospital
149 13th Street
Charlestown, Massachusetts 02129
Suzanne Imbriglio (617) 726-0874
Keith Malarick, BS
Phone: (513) 558-6555
Phone: (617) 726-0874
Merit E. Cudkowicz, MD, MSc
Dr. Merit Cudkowicz is the Julianne Dorn Professor of Neurology at Massachusetts General Hospital, at Harvard Medical School. Dr. Cudkowicz completed medical training at the Health Science and Technology program of Harvard Medical School, and she was a resident in Neurology at Mass General. She obtained a Master’s degree in Clinical Epidemiology from the Harvard School of Public Health. Dr. Cudkowicz’s research and clinical activities are dedicated to the study and treatment of patients with neurodegenerative disorders, in particular amyotrophic lateral sclerosis (ALS). Dr. Cudkowicz directs the Mass General ALS clinic and the Neurological Clinical Research Institute (NCRI) (formerly the NCTU). She is one of the founders and co-directors of the Northeast ALS Consortium (NEALS), a group of 92 clinical sites in the United States and Canada dedicated to performing collaborative academic led clinical trials in ALS. In conjunction with the NEALS consortium, she planned and completed seven multi-center clinical trials in ALS and is currently leading three new trials in ALS. Dr. Cudkowicz received the American Academy of Neurology 2009 Sheila Essay ALS award. She is actively mentoring young neurologists in clinical investigation. Dr. Cudkowicz is on the Research Council of the American Acadenmy of Neurology and the medical advisory board for the Muscular Dystrophy Association.
Diana Rosas Herminia, MD
Dr. Rosas and her team have focused primarily on the development of biomarkers for use in the study of neurodegenerative diseases, to better characterize progression, to better understand genotype/phenotype correlations, and to apply novel neuroimaging approaches in clinical trials with the overall aim of making them more efficient. We have begun to develop models that may explain clinically heterogeneous phenotypes and variability in disease progression. The current models for both disease prediction and prediction of disease progression are insensitive and inaccurate. We are planning to expand our efforts to include multi-modal and multi-spectral imaging approaches that promise both more precise measurements and made provide novel and important information on the neural underpinnings of HD and their clinical consequences.
Steve Hersch, MD, PhD
Dr. Hersch’s clinical and research interests are in neurodegenerative disorders and particularly Huntington’s disease (HD). He was recruited to MGH/Harvard Medical School in 2001 to direct the HD clinical center and develop a laboratory devoted to translational research for HD. Dr. Hersch’s work on HD has spanned basic, translational, and clinical and has included the neuropathology of HD, its pathogenesis, the development of therapeutics, and the development of clinical and biological measures of HD in humans to improve testing potential therapies.
His laboratory has examined the roles of huntingin protein in pathogenesis, the contributions of transcriptional dysfunction and cellular energetics to HD pathogenesis, and has extensively used HD mouse models to examine mechanisms of disease and explore potential therapies. Many of the compounds the Hersch lab has helped explore in HD mice are advancing through clinical trials. Dr. Hersch has been a principal investigator, steering committee member, or site investigator for many observational or therapeutic studies in HD patients. He has developed and holds INDs for potential disease modifying therapies for HD, which have gone to phase II and phase III clinical trials. He is leading a collaborative NIH supported program to develop neuroimaging, protein, small molecule, and genomic biomarkers of HD. He is also co-chair of the executive committee of the Huntington Study Group (HSG) and plays a major role in the planning and execution of multicenter clinical trials for HD. He also directs clinical care for HD provided by the New England Center of Excellence for Huntington’s disease and sees patients in the Movement Disorders unit at MGH.